Completion of this Series A financing, led by Chicago Atlantic, will help accelerate expansion

CHICAGO, June 3, 2024 — Workbox, the Chicago-based national workspace operator, who has seen remarkable growth since its inception in 2019, successfully raised $17.5 million in its Series A equity round with a follow-on option to secure an additional $5.5 million. To date, Workbox has raised over $25 million in total capital ahead of its follow-on allocation.

Led by Chicago Atlantic, this round of funding will help Workbox accelerate its growth across the United States. With ten locations in five cities, Workbox is one of the fastest-growing operators in the nation, most recently announcing new locations in Chicago and Dallas this month. The additional capital provides significant liquidity to expand Workbox at a time when much of the sector remains heavily capital constrained.

“The flexible office sector stands to be the single biggest driver of office space demand in this new era of work,” said John Wallace, Co-Founder and CEO of Workbox. “We see the term ‘flexible office’ becoming synonymous with ‘office,’ a sentiment already validated through the growth in hybrid employment, employee flexibility, geographically fragmented workforces, double income households, and the rapid acceleration of small business formation.”

“Workbox has more than doubled its revenue annually since inception, but it took a capital partner with the ability to look beyond office market headlines to see the true size of our opportunity in this trillion-dollar sector. The current environment has opened a path for reimagining the workplace and realigning owner and operator interests in a sustainable way,” said Wallace. “Chicago Atlantic brings over $2.1 billion in AUM, investment experience in both private equity and credit, public markets experience through a NASDAQ-listed REIT, and a nuanced understanding of how operating structure and design affect industry successes and failures.”

John Mazarakis, Founding Partner at Chicago Atlantic, added that “Workbox has been quietly pioneering the industry in both customer acquisition and structure innovation since it began. We’ve been impressed by its hands-on approach to operations and management, a strategy we believe will sustain their growth and performance long-term. We are proud to utilize Workbox for our firm and to build on our partnership with this significant investment.”

About Workbox
Workbox Holdings, Inc. is a national workspace operator that provides professionals with a platform to connect. In addition to traditional office space and coworking solutions, it offers access to a range of investors, a vetted network of professional specialists, and powerful interactions through a heavy concentration of high growth businesses across its entire portfolio. Web: www.workboxcompany.com

About Chicago Atlantic
Chicago Atlantic is a private market alternative investments manager focused on industries and companies where demand for capital exceeds traditional supply. Founding Partners John Mazarakis, Tony Cappell and Andreas Bodmeier established Chicago Atlantic in 2019. The firm’s private investment strategies have grown to include opportunistic credit and equity with focuses on loans to esoteric industries, specialty asset-based loans, liquidity solutions and growth and technology finance. Chicago Atlantic has made over $2 billion in credit and equity investments to date. Chicago Atlantic’s team of over 75 professionals has offices in Miami, Florida and Chicago, Illinois. For more information on Chicago Atlantic’s financing products, visit www.chicagoatlantic.com 

MEDIA CONTACT
Austin Taylor
Workbox
312.766.2928
[email protected]

SOURCE Workbox

SAN FRANCISCO, June 3, 2024 — Ashby, a recruiting platform that efficiently scales hiring from startup through enterprise, has raised an additional $30 million in equity financing. This round of funding comes with a vote of confidence from existing investors following a 6X growth in revenue. Lachy Groom, who also led Ashby’s seed round, led the Series C with participation from Elad Gil, F-Prime, Y Combinator, and existing Ashby customers. To date, the company has raised roughly $70M.

This latest round of financing will enable Ashby to continue its rapid pace of product development and enterprise expansion.

“At its best, fundraising accelerates something that is already going really well. We’re fortunate to have found ourselves in that position and as a result, we’ve decided to pull forward our Series C by a couple of quarters,” said Benjamin Encz, Co-Founder and CEO of Ashby.

“It’s been amazing to see Ashby’s growth and product velocity in the last few years,” said Lachy Groom, “Despite a tricky market, Ashby has 6x’d the business since the Series B and has garnered a lot of love from customers in a space that historically had really low NPS. In the current environment, more and more talent teams are looking to consolidate tools and ‘do more with less’ and Ashby, which is packed with automation and AI-enabled features, is perfectly positioned to benefit from that trend.”

“It’s the first ATS I’ve ever been impressed with,” said Veronica Salcido, Head of Global Talent at Multiverse. “We were looking for an innovative partner that was looking to build the future of talent acquisition, not one stuck in the way things had been done 10, 20 years ago. And in switching to Ashby All-in-One I got rid of a lot of vendors we no longer needed, so that made me look absolutely brilliant to my finance team.” 

About Ashby

Ashby was founded in late 2018 by Benjamin Encz and Abhik Pramanik. The company emerged from stealth mode at the time of their Series B announcement in September 2022, and have since then grown to support over 1,300 customers that range from some of the fastest growing startups in the world to some of the most cutting edge enterprises with 18K+ employees.

The product continues to differentiate on the quality and accessibility of talent team data, which serves as a foundation for seamless workflows, powers unique AI functionality that improves efficiency and personalization, and consolidates the full recruiter workflow into one system versus multiple point solutions. Layered on top is the quality of their customer experience, proprietary data reports, and commitment to the talent community.

Supporting the strong growth and ambitious product roadmap, Ashby has made a number of additional key hires including VP of People and Talent Jim Miller (15 years at Google shaping their internal ATS, GHire), VP of Finance Shane Gallaher (first FP&A hire at Fastly), VP of Customer Success Kelsey Peterson (HubSpot and early startups), Head of Support Allie Hurley (ClickUp), Head of EMEA Sales Jack Hanratty (Asana and LinkedIn), as well as a number of top talent leaders and operators.

Learn more at ashbyhq.com 
Follow our updates and trend reports on LinkedIn
Contact: [email protected]

SOURCE Ashby

SAN FRANCISCO, June 3, 2024 — Stackless Data, a leading provider of data-driven solutions, is excited to announce the release of its latest resource, “The Seller’s Playbook for Increasing CLV and Reducing CAC.” Stackless Data is offering this playbook as a free download, emphasizing the company’s commitment to empowering retailers and CPG leaders to elevate their businesses.

Recognizing that customers lie at the heart of any successful business, Stackless Data underscores the vital importance of prioritizing Customer Lifetime Value (CLV) and reducing Customer Acquisition Cost (CAC) for sustained brand success. The playbook provides a roadmap for transitioning from a traditional funnel-based sales approach to a dynamic flywheel model.

The Seller’s Playbook delves into the core principles of the flywheel sales model, showcasing how it stands in contrast to the conventional sales funnel. The flywheel model represents a shift from a linear, one-way sales process to a circular and self-reinforcing system. In essence, it views customer interactions as a continuous cycle, with each positive engagement propelling the wheel forward.

“We believe that in order to secure long-term success, retailers and CPG leaders must embrace a holistic data strategy that revolves around customer relationships,” says Nachi Mehta, CEO of Stackless Data. “The flywheel sales model introduces a more dynamic and sustainable approach, fostering customer loyalty and advocacy.”

Within the playbook, readers will gain insights into the fundamental concepts of the flywheel model and discover how it contributes to increased Customer Lifetime Value. Practical tips and strategies will be shared, allowing brands to implement actionable steps to enhance CLV while simultaneously reducing CAC.

“The Seller’s Playbook aims to be a valuable resource for businesses looking to thrive in a competitive market,” adds Mehta. “By orienting data capture and usage the flywheel sales model, retailers and CPG leaders can create a positive feedback loop that benefits both the brand and the customer.”

Stackless Data invites businesses and industry professionals to download “The Seller’s Playbook for Increasing CLV and Reducing CAC” for free https://stacklessdata.com/sellers-playbook. Empower your brand with the insights needed to forge stronger customer relationships, optimize marketing efforts, and ultimately drive sustainable growth.

About Stackless Data
Stackless Data provides a data readiness platform that empowers businesses to unlock the full potential of their data while slashing data intelligence total cost of ownership by 70% and giving lightning-fast time to value. With a commitment to efficiency, cost savings, and strategic insights, Stackless Data is at the forefront of revolutionizing the way companies approach and utilize their data.

For media inquiries, contact:
Fritz Rollins
415-846-3773
[email protected]

SOURCE Stackless Data

Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential

SAN DIEGO, June 3, 2024 — Psylo, a leading biotechnology company focused on the development of next-generation neuroplastogens, today announced at the BIO Conference in San Diego the successful first close toward an $8 million USD Series Seed financing. This funding will accelerate the advancement of PSYLO-100X, the company’s flagship non-hallucinogenic 5-HT2A agonist, poised to revolutionize the treatment of depression and other mental health disorders.

PSYLO-100X distinguishes itself from first-generation psychedelics by eliciting neuronal remodeling without causing hallucinatory effects. This breakthrough compound demonstrates antidepressant-like effects in vivo and promotes neuroplasticity in vitro, while notably avoiding activation at the 5-HT2B receptor—a critical safety feature due to the cardiotoxicity risk associated with activation of this receptor.

“We are thrilled to announce this funding milestone at the BIO Conference,” said Joshua Ismin, CEO of Psylo. “This capital raise underscores strong confidence in Psylo’s unique translational approach and the therapeutic potential of our pipeline. Our platform has yielded a non-hallucinogenic candidate designed to be safely administered at home without clinical supervision, and serves to advance our mission to address the mental health crisis for a broader patient population.”

The Series Seed financing was led by Tenmile, a leading Health investor, with participation from Palo Santo, Focalpoint Ventures (formerly Empath Ventures), Mystic Ventures, and Gaingels. Dr. Steve Burnell, Managing Director of Tenmile, expressed enthusiasm for the investment: “We have been incredibly impressed with Psylo’s progress and the innovative approach they are taking to address mental health disorders. We are pleased to be investing in Psylo and are confident in their ability to advance PSYLO-100X, which we believe has the potential to make a significant impact in the neuro space.”

Key Highlights of PSYLO-100X:

• Non-hallucinogenic: Unlike traditional psychedelics, PSYLO-100X has been designed to remove hallucinatory effects, making it a safer and more accessible treatment option.
• Partially selective 5-HT2A agonist: PSYLO-100X selectively targets the 5-HT2A receptor without activating the 5-HT2B receptor, reducing the risk of cardiotoxicity.
• Promotes neuroplasticity: Increases the complexity of neurons in cell culture, suggesting potential for long-term therapeutic benefits.
• Antidepressant effects: Demonstrative pro-cognitive effects in vivo, offering a promising new treatment for depression, anxiety, and other ruminative disorders.

“After three years of rigorous drug-discovery, we’re hugely encouraged by our progress,” noted Dr. Samuel Banister, Chief Scientific Officer at Psylo. “PSYLO-100X is a non-tryptamine, non-phenethylamine compound with a hugely promising preclinical profile. We believe this novel approach marks a significant leap forward in developing safer, more effective treatments.”

Psylo plans to utilize the Series Seed funds to continue to invest in their drug discovery platform, and advance PSYLO-100X through IND enabling studies, with the goal of initiating first in human clinical trials in 2025.

Founded in Australia, Psylo recently restructured to become a US Delaware C-corp in-line with the fundraise, and has established labs at the University of Colorado Boulder and the University of New South Wales in Sydney. For more information about Psylo and its groundbreaking work in neuroplastogens, visit www.psylo.bio

About Psylo

Psylo is a biotechnology company dedicated to developing next-generation neuroplastogens to treat mental health disorders. By leveraging cutting-edge science and innovative therapeutic approaches, Psylo aims to transform the mental health landscape and improve the lives of millions worldwide.

SOURCE Psylo

CHARLOTTESVILLE, Va., June 3, 2024 — Caju AI, a leading innovator in Generative AI-powered solutions for customer engagement, is pleased to announce the successful closure of a $3 million Seed financing round. This strategic investment is backed by Grotech Ventures, Felton Group, the family office of Charlottesville, VA based hedge fund manager Jaffray Woodriff, and angel investors. This funding milestone propels Caju AI into a new phase of growth and innovation, reinforcing its position as a leader in AI-driven customer engagement and compliance solutions.

Empowering Next-Generation Customer Engagement

Caju AI’s platform, renowned for its robust Generative AI capabilities, securely captures and analyzes customer communications across all messaging channels as well as customer engagement data to deliver advanced analytics for conversation intelligence, call summaries, regional activity monitoring, key trend analysis, and actionable business intelligence, all designed to accelerate field engagement and enhance customer satisfaction across the enterprise. At the same time, Caju AI ensures regulatory compliance, prevents data loss, and mitigates other risk concerns.

“Most enterprises do not have visibility into digital conversations or understand all customer interactions across their organization, either for business insights or risk protection. Our platform delivers a highly innovative, Gen AI-driven conversation intelligence solution to provide enterprise-level analysis as a comprehensive end-to-end solution,” said Otavio Freire, CEO and Co-Founder of Caju AI.

Strategic Investment for Future Growth

The investment from Grotech Ventures and Felton Group underscores the confidence in Caju AI’s vision and technological prowess. Grotech Ventures, renowned for backing transformative tech companies, and Felton Group, the early-stage investment arm of AI hedge fund titan Jaffray Woodriff, bring capital and strategic expertise to accelerate Caju AI’s market expansion.

“Caju AI is at the forefront of a tech revolution that empowers organizations to harness the full potential of Generative AI while ensuring compliance and security,” said Steve Fredrick, Partner at Grotech Ventures. “We are thrilled to support their journey and witness the transformative impact they will have on customer interaction.”

About Caju AI

The Caju AI platform assists organizations in capturing communications and customer engagement data while ensuring privacy, security, and compliance. Utilizing the remarkable capabilities of generative artificial intelligence to comprehend human conversations, Caju AI quickly analyzes messaging and customer records across the organization on a large scale. It delivers actionable intelligence that empowers teams to provide exceptional customer service, foster stronger relationships, and drive superior business results. The Caju platform is rapidly becoming essential for the financial services, pharmaceutical, healthcare, education, and government sectors.

For more information, visit Caju AI

About Grotech Ventures

Grotech Ventures is a leading early-stage venture capital firm with a history of backing innovative technology companies. With a focus on enterprise software, security, and digital media, Grotech Ventures partners with visionary entrepreneurs to build market-leading businesses.

About Felton Group

Felton Group, the family office of Jaffray Woodriff, is dedicated to investing in early-stage technology companies with a focus in Charlottesville and Central Virginia. With a strong track record of supporting transformative businesses, Felton Group is pivotal in fostering innovation and growth.

SOURCE Caju AI

TEL AVIV, Israel, June 3, 2024 — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce that it is in the process of applying to the TSX Venture Exchange in Canada to list its shares at a proposed valuation of 40 million Canadian dollars.

About Zero Candida:

ZC is a private FemTech technology company incorporated under the corporate laws of the State of Israel. ZC is developing an AI smart tampon-like device based on AI on a therapeutic light source with a selected wave-length and intensity that can treat the Candida fungus with successfully of 99.999% an POC. Vulvo-Vaginal Candidiasis (“VVC”) affects about 75% of women globally, each year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments and constitutes up to 10% of the cases of VVC. Existing treatments are unable to overcome the high rate of recurrence, since the root cause of the condition is poorly understood and addressed.

ZC has signed pre-clinical agreements with hospitals in Israel and Europe and the company has successfully completed a safety trial for the use of a pre-clinical device in large animals (sheep) ZC continues the development of the final product for human use in preparation for a clinical trial that took place in June 2025.

Zero Candida’s device will bring the field of gynecology into the 21st century with hybrid medicine and technology-based diagnostics. At the same time as developing the treatment procedure, Zero Candida is working on creating a technology to enable the hybrid medicine services to be provided by gynecologists to populations that until now received no treatment at all, including, among others, in the developing countries.

Summary of Transaction

Pursuant to the business combination agreement (the “Agreement”) between a Canadian reporting issuer (the “Reporting Issuer”) and the Company, the transaction is expected to be contemplated by a three-cornered amalgamation, where the Reporting Issuer’s wholly owned Israeli subsidiary incorporated solely for the purpose of the transaction, is expected to amalgamate with ZC. Each holder (each a ” ZC Shareholder”) of ZC Share, other than a ZC Shareholder who exercised Dissent Rights (as defined in the Israeli Companies Law) is expected to receive 8.6277 eight and six thousand two hundred seventy seven ten-thousandths) shares in the capital of the Reporting Issuer (each a “Resulting Issuer Share”) in exchange for each ZC Share held by such ZC Shareholder, resulting in the Company issuing up to an aggregate of 12,223,232 Resulting Issuer’s Shares (which will represent approximately 85.94% of the issued and outstanding Resulting Issuer Shares, without taking into consideration any ZC share purchase warrants to be exercised immediately prior to completion of the Transaction, stock options or a concurrent financing). Additionally, the holders of stock options of ZC will be entitled to receive Resulting Issuer Shares, instead of ZC Shares, on the exercise of their options.

Eli Ben Haroosh, Founder & CEO: “Zero-Candida’s technology is a game changer that will change the treatment of women and FemTech industry in the world. Zero Candida’s technology, first of its kind using a controlled “Blue Light”, destroys the fungus at record speed and without side effects. The treatment is carried out by a tampon-like medical device which, according to medical experts, provides an optimal solution for removing the fungus altogether, preventing the recurrence of the disease. Another significant advantage of the Zero Candida device is treatment without side effects, in a world where many of us try to improve our health without the use of chemicals. We foresee an amazing future for Zero Candida in the medical devices’ world. Zero Candida has a potential to become a technological leader and using its ground-breaking technology to expand boundaries of non-chemical candida treatment”.

Dr. Asher Holtzer, Director: “the invention of Zero Candida can potentially become a game changer in the world, the company brings amazing news to FemTech women’s care and can become a leader in women’s health all over the world. According to studies in the world, 3 out of 4 women, approximately 75%, suffer during their lifetime from Candida disease, a fungal infection that attacks large parts of the female reproductive system, which causes significant damage to the quality of life and, in severe cases, even disability. Until now, the common treatments for candida included antifungal drugs that alleviated the symptoms but failed to solve the problem at its root”.

Contact:
Eli Ben Haroosh, CEO & Founder
E: [email protected]
Website : www.Zero-Candida.com
Facebook: @Zero-candida

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Logo – https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg

SOURCE Zero Candida